Werewolf Therapeutics Q1 net loss $12.0M; COO retiring; WTX-124 data expected 4Q23

Werewolf Therapeutics, Inc.

2023-Q1 EPS reported -$0.34

Net loss of $12.0M improved from $15.3M in Q1 2022; cash and equivalents $147.9M.
Collaboration revenue of $4.5M from Jazz Pharma licensing agreement; R&D spend $11.7M.
COO Reid Leonard retiring effective June 30, 2023; founding executive team member.
Phase 1/1b WTX-124 monotherapy data (safety, tolerability, efficacy) expected 4Q 2023.
New candidate WTX-712 (IL-21 INDUKINE) preclinical data presented at AACR 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Werewolf Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue Collaboration revenue was $4.5 million.

Period: the first quarter ended March 31, 2023
Revenue: Collaboration revenue was $4.5 million
Result: reported results

Exact text from the filing

sufficient to fund its operational expenses and capital expenditure requirements through at least the fourth quarter of 2024. • Collaboration revenue: Collaboration revenue was $4.5 million for the first quarter of 2023, compared to zero for the same period in 2022. Collaboration revenue is related to partial recognition of the $15.0 million upfront payment received

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-23-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.